CryoLife Pursues SynerGraft Heart Valve Trial, ACL, Vascular Applications
This article was originally published in The Gray Sheet
Executive SummaryCryoLife's clinical trial for the firm's SynerGraft replacement heart valve would enroll 150 pediatric patients over a 12-18 month period and possibly extend the study after the first 6-12 months to include adults.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.